The proportion of free to total prostate specific antigen: A method of detecting prostate carcinoma

Cancer

Volumn 77, Issue 6, 1996, Pages 1137-1143

  Demura, Takayoshi ^a   Shinohara, Nobuo ^a   Tanaka, Motoyoshi ^a   Enami, Nobuyasu ^a   Chiba, Hitoshi ^a   Togashi, Masaki ^b   Ohashi, Nobuo ^b   Nonomura, Katsuya ^a   Koyanagi, Tomohiko ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b SAPPORO CITY GENERAL HOSPITAL   (Japan)

Author keywords

diagnosis; gamma seminoprotein; prostate carcinoma; prostate specific antigen

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; GAMMA SEMINOPROTEIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; COMPLEX FORMATION; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; RADIOIMMUNOASSAY;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0029879422     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960315)77:6<1137::AID-CNCR20>3.0.CO;2-1     Document Type: Article

References (31)

1. Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980;40:4658-62.
2. Guinan P, Bhatti R, Ray P. An evaluation of prostate specific antigen in prostate cancer. J Urol 1987;137:686-9.
3. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:747-52.
4. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ-J, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
5. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317: 909-16.
6. Siddall JK, Sherry SD, Cooper EH, Measurement of serum γ-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate. Clin Chem 1986;32:2040-3.
7. Kuriyama M, Takeuchi T, Shinoda I, Okano M, Nishiura T. Clinical evaluation of γ-seminoprotein in prostate cancer. Prostate 1986;8:301-11.
8. Yoshiki T, Okada K, Oishi K, Yoshida O. Clinical significance of tumor markers in prostatic carcinoma: comparative study of prostatic acid phosphatase, prostate specific antigen and γ-seminoprotein. Acta Urol Jpn 1987;33:2044-9.
9. Ishihara Y, Hiromoto Y, Higaki Y, Imamura K. Clinical evaluation of serum γ-seminoprotein in patients with prostatic cancer. Acta Urol Jpn 1989;35:409-13.
10. Hara M, Koyanagi Y, Inoue T, Fukuyama T. Some physiochemical characteristics of gamma-seminoprotein: an antigenic component specific for human plasma. Jpn J Legal Med 1971;25:322-4.
11. Schaller J, Akiyama K, Tsuda R, Hara M, Marti T, Rickle E. Isolation, characterization and amino-acid sequence of γ-seminoprotein from human seminal plasma. Eur J Biochem 1987;170:111-20.
12. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987;214:317-22.
13. Demura T, Watarai Y, Togashi M, Hirano T, Ohashi N, Koyanagi T. Measurement of prostate specific antigen/gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer. J Urol 1993;150: 1740-5.
14. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
15. Lilja H, Cockett ATK, Abrahamsson PA. Prostate specific antigen predominandy forms a complex with alpha1-antichymotrypsin in blood. Cancer 1992;70:230-4.
16. McCormack RT, Wang TJ, Rittenhouse HG, Wolfert RL, Finlay JA, Lilja H, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995;45:729-44.
17. Kawakami K, Tsukada T, Nakayama T. Analysis on inhibitory reaction of γ-Sm, a marker for prostate cancer. Jpn J Clin Pathol 1992;40(Suppl):245.
18. Stamey TA, Chen Z, Prestigiacomo A. Serum prostate specific antigen binding a1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones. J Urol 1994;152:1510-4.
19. Wu JT. Assay for prostate specific antigen (PSA): problems and possible solutions. J Clin Lab Anal 1994;8:51-62.
20. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen MT, Cockett ATK, et al. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
21. Luderer AA, Chen Y-T, Soriano TF, Kramp WJ, Carlson G, Cuny C, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46:187-94.
22. Miki M, Machida T, Yanagisawa M, Yoshida M, Yamazaki H, Kondo N, et al. Clinical evaluation of serum prostatic specific antigen measurement by radioimmunoassay. Jpn J Urol 1984;75:1982-8.
23. Kuriyama M, Akimoto S, Akaza H, Arai Y, Usami M, Imai K, et al. Comparison of various assay system for prostate-specific antigen standardization. Jpn J Clin Oncol 1992;22:393-9.
24. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
25. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
26. Kamushida S, Tsutsumi Y. Extraprostatic localization of prostatic acid phosphatase and prostate specific antigen: distribution in cloacogenic glandular epithelium and sex dependent expression in human anal gland. Hum Path 1990;21:1108-11.
27. Frazier HA, Humphrey PA, Burchette JL, Paulson DF. Immunoreactive prostatic specific antigen in male periurethral glands. J Urol 1992;147:246-8.
28. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
29. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value or intermediate levels of serum prostate specific antigen. J Urol 1992;147:817-21.
30. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270:948-54.
31. Jewett HJ. The present status of radical prostatectomy for stage A and B prostatic cancer. Urol Clin North Am 1975;2:105-24.